Steve Damment
Founder bei Aluztura Bio Ltd.
Profil
Steve Damment is the founder of Aluztura Bio Ltd.
which is founded in 2014, where he holds the title of Chief Science Officer.
He held the position of Senior Vice President-Biosciences at Shire Plc from 2000 to 2013 and at GSK Plc from 1982 to 1999.
He also held the position of Executive Vice President-Research & Development at Biodexa Pharmaceuticals Plc from 2018 to 2021.
Dr. Damment received his undergraduate degree from The University of Liverpool.
Aktive Positionen von Steve Damment
| Unternehmen | Position | Beginn |
|---|---|---|
| Aluztura Bio Ltd. | Founder | 01.01.2014 |
Ehemalige bekannte Positionen von Steve Damment
| Unternehmen | Position | Ende |
|---|---|---|
| BIODEXA PHARMACEUTICALS PLC | Chief Tech/Sci/R&D Officer | 30.09.2021 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01.12.2013 |
| GSK PLC | Corporate Officer/Principal | 01.12.1999 |
Ausbildung von Steve Damment
| The University of Liverpool | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GSK PLC | Health Technology |
| BIODEXA PHARMACEUTICALS PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
| Aluztura Bio Ltd. |
